• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

半乳糖凝集素-3 与 HFpEF:阐明一种新兴关系。

Galectin-3 and HFpEF: Clarifying an Emerging Relationship.

机构信息

School of Medicine, Stanford University, Stanford, California, USA.

Department of Nanoscience, Brown University, Providence, Rhode Island, USA.

出版信息

Curr Cardiol Rev. 2023;19(5):19-26. doi: 10.2174/1573403X19666230320165821.

DOI:10.2174/1573403X19666230320165821
PMID:36959138
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10518880/
Abstract

INTRODUCTION

HFpEF is one of the leading causes of death whose burden is estimated to expand in the coming decades. This paper examines the relationship between circulating levels of galectin-3, an emerging risk factor for cardiovascular disease, and the clinical diagnosis of HFpEF.

METHODS

The authors reviewed peer-reviewed literature and 18 studies met the inclusion criteria. Study characteristics, study outcome definitions, assay characteristics, main findings, and measures of association were tabulated and summarized.

RESULTS

Five studies found significant associations between galectin-3 and HFpEF diagnosis compared to healthy controls, and one did not. Five studies found significant associations between galectin- 3 concentration in circulation and severity of diastolic dysfunction. Three studies found a statistically significant association between circulating galectin-3 and all-cause mortality or rehospitalization. Two studies found levels of circulating galectin-3 to be a statistically significant predictor of later HFpEF onset. Finally, two studies examined whether galectin-3 was associated with incident HFpEF, one found a significant association and the other did not.

CONCLUSION

Given the paucity of effective therapeutics for HFpEF, galectin-3 shows promise as a possible HFpEF-linked biomarker that may, with further study, inform and predict treatment course to reduce morbidity and mortality.

摘要

简介

HFpEF 是导致死亡的主要原因之一,其负担预计在未来几十年内会增加。本文研究了循环中半乳糖凝集素-3(一种新兴的心血管疾病风险因素)的水平与 HFpEF 的临床诊断之间的关系。

方法

作者回顾了同行评议的文献,并纳入了 18 项符合条件的研究。列出并总结了研究特征、研究结果定义、检测特征、主要发现和关联测量。

结果

五项研究发现,与健康对照组相比,半乳糖凝集素-3与 HFpEF 诊断之间存在显著关联,一项研究未发现显著关联。五项研究发现,循环中半乳糖凝集素-3浓度与舒张功能障碍的严重程度之间存在显著关联。三项研究发现,循环中半乳糖凝集素-3与全因死亡率或再住院率之间存在统计学显著关联。两项研究发现,循环中半乳糖凝集素-3水平是 HFpEF 后期发病的统计学显著预测因素。最后,两项研究检查了半乳糖凝集素-3是否与 HFpEF 发病有关,一项研究发现存在显著关联,另一项研究则未发现。

结论

鉴于 HFpEF 的有效治疗方法有限,半乳糖凝集素-3作为一种可能的 HFpEF 相关生物标志物具有一定的前景,进一步的研究可能会为治疗方案提供信息并进行预测,以降低发病率和死亡率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb97/10518880/7ea5caa91fec/CCR-19-E200323214796_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb97/10518880/7ea5caa91fec/CCR-19-E200323214796_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb97/10518880/7ea5caa91fec/CCR-19-E200323214796_F1.jpg

相似文献

1
Galectin-3 and HFpEF: Clarifying an Emerging Relationship.半乳糖凝集素-3 与 HFpEF:阐明一种新兴关系。
Curr Cardiol Rev. 2023;19(5):19-26. doi: 10.2174/1573403X19666230320165821.
2
The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study.半乳糖凝集素-3在射血分数保留的心力衰竭高危患者中的诊断和预后价值:DIAST-CHF研究结果
ESC Heart Fail. 2021 Apr;8(2):829-841. doi: 10.1002/ehf2.13174. Epub 2021 Feb 10.
3
The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review.生长分化因子 15、半乳糖凝集素 3 和可溶性 ST2 作为心力衰竭保留射血分数和心力衰竭射血分数降低的诊断生物标志物的效用:系统评价。
Heart Fail Rev. 2021 Jul;26(4):799-812. doi: 10.1007/s10741-020-09913-3.
4
Galectin-3 in heart failure with preserved ejection fraction.心脏射血分数保留型心力衰竭中的半乳糖凝集素-3。
Eur J Heart Fail. 2013 Oct;15(10):1095-101. doi: 10.1093/eurjhf/hft077. Epub 2013 May 5.
5
Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction.半乳糖凝集素-3对射血分数保留的急性心力衰竭患者中脑钠肽的附加价值。
Clin Chim Acta. 2016 Jun 1;457:99-105. doi: 10.1016/j.cca.2016.04.007. Epub 2016 Apr 8.
6
Galectin-3 is Associated with Heart Failure Incidence: A Meta-Analysis.半乳糖凝集素-3 与心力衰竭发生率相关:一项荟萃分析。
Curr Cardiol Rev. 2023;19(3):e171122211004. doi: 10.2174/1573403X19666221117122012.
7
Biomarker profiling for risk of future heart failure (HFpEF) development.用于预测未来发生射血分数保留的心力衰竭(HFpEF)风险的生物标志物分析。
J Transl Med. 2021 Feb 9;19(1):61. doi: 10.1186/s12967-021-02735-3.
8
Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial.心力衰竭伴射血分数保留患者的半乳糖凝集素-3:Aldo-DHF 试验结果。
Eur J Heart Fail. 2015 Feb;17(2):214-23. doi: 10.1002/ejhf.203. Epub 2014 Nov 24.
9
Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction.血清半乳糖凝集素-3水平在射血分数保留的心力衰竭中的诊断意义
Acta Cardiol. 2016 Apr;71(2):191-7. doi: 10.2143/AC.71.2.3141849.
10
Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction.心血管生物标志物与射血分数保留和降低的心力衰竭事件的相关性。
JAMA Cardiol. 2018 Mar 1;3(3):215-224. doi: 10.1001/jamacardio.2017.4987.

引用本文的文献

1
Biomarkers in Heart Failure with Preserved Ejection Fraction: A Perpetually Evolving Frontier.射血分数保留的心力衰竭中的生物标志物:一个不断发展的前沿领域。
J Clin Med. 2024 Aug 7;13(16):4627. doi: 10.3390/jcm13164627.
2
Understanding Galectin-3's Role in Diastolic Dysfunction: A Contemporary Perspective.了解半乳糖凝集素-3在舒张功能障碍中的作用:当代观点。
Life (Basel). 2024 Jul 20;14(7):906. doi: 10.3390/life14070906.
3
Identifying plasma proteomic signatures from health to heart failure, across the ejection fraction spectrum.从健康到心力衰竭,跨越射血分数谱识别血浆蛋白质组学特征。

本文引用的文献

1
Galectin-3 is Associated with Heart Failure Incidence: A Meta-Analysis.半乳糖凝集素-3 与心力衰竭发生率相关:一项荟萃分析。
Curr Cardiol Rev. 2023;19(3):e171122211004. doi: 10.2174/1573403X19666221117122012.
2
Did giraffe cardiovascular evolution solve the problem of heart failure with preserved ejection fraction?长颈鹿的心血管进化是否解决了射血分数保留的心力衰竭问题?
Evol Med Public Health. 2021 Jun 11;9(1):248-255. doi: 10.1093/emph/eoab016. eCollection 2021.
3
The Leading Causes of Death in the US for 2020.2020年美国的主要死因。
Sci Rep. 2024 Jun 27;14(1):14871. doi: 10.1038/s41598-024-65667-0.
4
The Role of Galectin-3 in Predicting Congenital Heart Disease Outcome: A Review of the Literature.半乳糖凝集素-3 在预测先天性心脏病结局中的作用:文献综述。
Int J Mol Sci. 2023 Jun 22;24(13):10511. doi: 10.3390/ijms241310511.
JAMA. 2021 May 11;325(18):1829-1830. doi: 10.1001/jama.2021.5469.
4
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.PRISMA 2020 声明:系统评价报告的更新指南。
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
5
The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study.半乳糖凝集素-3在射血分数保留的心力衰竭高危患者中的诊断和预后价值:DIAST-CHF研究结果
ESC Heart Fail. 2021 Apr;8(2):829-841. doi: 10.1002/ehf2.13174. Epub 2021 Feb 10.
6
Biomarker profiling for risk of future heart failure (HFpEF) development.用于预测未来发生射血分数保留的心力衰竭(HFpEF)风险的生物标志物分析。
J Transl Med. 2021 Feb 9;19(1):61. doi: 10.1186/s12967-021-02735-3.
7
Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis.2 型糖尿病与射血分数中间值和保留的慢性心力衰竭:关注纤维化的血清生物标志物。
J Diabetes Res. 2020 Nov 7;2020:6976153. doi: 10.1155/2020/6976153. eCollection 2020.
8
Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction.评估半乳糖凝集素-3作为射血分数保留的心力衰竭患者新型诊断生物标志物的价值。
J Lab Physicians. 2020 Aug;12(2):126-132. doi: 10.1055/s-0040-1716608. Epub 2020 Sep 1.
9
Deaths: Leading Causes for 2017.死亡:2017年的主要死因。
Natl Vital Stat Rep. 2019 Jun;68(6):1-77.
10
Serum and Echocardiographic Markers May Synergistically Predict Adverse Cardiac Remodeling after ST-Segment Elevation Myocardial Infarction in Patients with Preserved Ejection Fraction.血清和超声心动图标志物可能协同预测射血分数保留的ST段抬高型心肌梗死患者心脏不良重构。
Diagnostics (Basel). 2020 May 14;10(5):301. doi: 10.3390/diagnostics10050301.